beta

ALEC

Alector, Inc.

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Alector, Inc. operates as a clinical-stage biopharmaceutical company. It develops therapeutics for the treatment of neurodegenerative diseases including frontotemporal dementia (FTD), Alzheimer's disease, and Parkinson's disease. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

Market Cap: 1.35 Billion

Primary Exchange: NASDAQ

Website: http://www.alector.com

Shares Outstanding: 68.9 Million

Float: 40.6 Million

Dividend: (%)

Beta: -0.583199189626407

Sector: Health Technology

Industry: Biotechnology

Ethical Flags

Longest drawdown: 179 trading days

From: 2019-04-12 To: 2019-12-09

Lowest Point:

Prevail Therapeutics Proposes IPO Terms

via: SeekingAlpha at 2019-06-13 07:46:25:000

Quick Take Prevail Therapeutics ( PRVL ) has filed to raise gross proceeds of $125 million from a U.S. IPO, according to an S-1/A registration statement . The firm is developing Adeno-Associated Virus-based [AAV-based] gene therapies for the treatment of serious neurodegenerative diseases… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud